Priority Research Papers:
Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer
Metrics: PDF 1540 views | HTML 2832 views | ?
Catherine Burkhart1, Daria Fleyshman2, Rachael Kohrn1, Mairead Commane2, Jennifer Garrigan1, Vadim Kurbatov3, Ilya Toshkov1, Rajesh Ramachandran3, Laura Martello3 and Katerina V. Gurova2
1 Buffalo Biolabs, LLC, Buffalo, NY, USA
2 Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, USA
3 Division of Gastroenterology & Hepatology, SUNY Downstate Medical Center, Brooklyn, NY, USA
Katerina Gurova, email:
Keywords: curaxins, CBL0137, pancreatic cancer, gemcitabine, SSRP1, SPT16, cancer stem cells
Received: October 29, 2014 Accepted: November 06, 2014 Published: November 06, 2014
Pancreatic ductal adenocarcinoma (PDA) continues to be one of the deadliest cancers due to the absence of effective treatment. Curaxins are a class of small molecules with anti-cancer activity demonstrated in different models of cancer in mice. The lead curaxin compound, CBL0137, recently entered Phase I clinical trials. Curaxins modulate several important signaling pathways involved in the pathogenesis of PDA through inhibition of chromatin remodeling complex FACT. FACT is overexpressed in multiple types of tumor, with one of the highest rate of overexpression in PDA (59%). In this study, the efficacy of CBL0137 alone or in combination with current standard of care, gemcitabine, was tested against different models of PDA in vitro and in mouse models. It was found that CBL0137 alone is a potent inducer of apoptosis in pancreatic cancer cell lines and is toxic not only for proliferating bulk tumor cells, but also for pancreatic cancer stem cells. In mice, CBL0137 was effective against several PDA models, including orthotopic gemcitabine resistant PANC-1 model and patient derived xenografts, in which CBL0137 anti-tumor effect correlated with overexpression of FACT. Moreover, we observed synergy of CBL0137 with gemcitabine which may be explained by the ability of CBL0137 to inhibit several transcriptional programs induced by gemcitabine, including NF-kappaB response and expression of ribonucleotide reductase, one of the targets of gemcitabine in cells. This data suggest testing of CBL0137 efficacy in Phase II trial in PDA patients alone and in combination with gemcitabine.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.